Developer docs
API playgroundTry for free, no card

Search company profiles

Pague Menos

Full company profile

uuid00044q8

Namestring
Pague Menos
Legal namestring
Pague Menos
Company typeenum
Private
Founded yearint
1981
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersCeará, Brazil
HQ citystring
Ceará
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Keyword5 values
retail pharmacy services, prescription medications, over-the-counter drugs, health and wellness products, drugstore retail
Industry2 codes
1Retail & Community Pharmacies (Chain/Independent)
CodeHLAFALAAPrimaryYes
2Value Pharmacies & Deep-Discount Pharmacy Retail
CodeCRAEAHABPrimaryNo
NAICS code1 code
  • Pharmacies and Drug Retailers456110
SIC code1 code
  • Retail-Drug Stores And Proprietary Stores5912
Product category
Retail Pharmacy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Retail Pharmacy Sales
TypeOne Time License
Description

Pague Menos generates revenue through the retail sale of pharmaceutical products, health items, and related consumer goods across its pharmacy store network in Brazil.

g1.globo.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Pague Menos operates a nationwide chain of retail pharmacies in Brazil, selling prescription medications, over-the-counter drugs, health and wellness products, and personal care items directly to individual consumers through physical storefronts. The chain's scale was significantly expanded through the 2021 acquisition of Extrafarma from Ultrapar for R$ 700 million, making it the second-largest drugstore operator in Brazil.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pague Menos is a Brazilian pharmacy chain retailer. The company operates as a retail pharmacy business offering pharmaceutical products and health-related goods to consumers. The company expanded its market presence through the acquisition of rival pharmacy chain Extrafarma from Ultrapar for R$ 700 million in 2021. No detailed product portfolio or service module information is available from the provided sources.

Product and service2 records
1Retail pharmacy sales
CategoryRetail pharmacy
Description

Retail sale of prescription medications, over-the-counter drugs, health and wellness products, and personal care items to Brazilian consumers through the Pague Menos physical pharmacy network.

2Extrafarma pharmacy retail operations
CategoryRetail pharmacy
Description

Wholly-owned retail pharmacy subsidiary offering pharmaceutical and health products under the Extrafarma brand, retained following Pague Menos's 2021 acquisition.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Ultrapar
Strategic tierCoreTypeOthersAnnounced on2021-03-18
Description

Pague Menos completed the acquisition of rival pharmacy chain Extrafarma from Ultrapar for R$ 700 million. This strategic transaction significantly expanded Pague Menos' market presence, making it the second-largest player in the Brazilian drugstore sector.

g1.globo.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Raia Drogasil (RD) is the largest drugstore chain in Brazil, formed from the merger of Drogaria Raia and Drogasil. It is Pague Menos's primary direct competitor, operating a similar physical retail pharmacy model with overlapping product categories including prescription, OTC, personal care, and wellness across Brazil.

TypeDirect peer
Description

DPSP is a major Brazilian pharmacy chain resulting from the combination of Drogaria São Paulo and Drogarias Pacheco, operating physical storefronts across multiple states. It directly competes with Pague Menos in the Brazilian drugstore retail sector with comparable product mix and customer base.

TypeDirect peer
Description

Panvel is a Brazilian pharmacy chain with a strong presence in the South region (Rio Grande do Sul and surrounding states), offering prescription drugs, OTC, beauty, and wellness products. It is comparable to Pague Menos as a multi-state physical retail pharmacy operator, though with a more regional footprint.

4Drogaria Araújo
TypeRegional player
Description

Drogaria Araújo is one of the largest pharmacy chains in Minas Gerais, operating a physical retail pharmacy network with comparable product categories to Pague Menos. It is comparable as a Brazilian physical pharmacy chain but operates primarily within a single state rather than nationally.

TypeRegional player
Description

Drogaria Venancio is a long-established pharmacy chain headquartered in Rio de Janeiro, operating physical storefronts with prescription, OTC, and health product offerings. It is comparable to Pague Menos as a Brazilian physical pharmacy retailer, though concentrated in the Rio de Janeiro metropolitan area.

TypeBroad incumbent
Description

CVS Health is the largest pharmacy retail chain in the United States, combining drugstores with pharmacy benefit management, insurance, and healthcare services. It is comparable to Pague Menos as a broad retail pharmacy operator at scale, though operating in a very different healthcare system.

TypeBroad incumbent
Description

Walgreens Boots Alliance operates one of the largest global pharmacy retail footprints including U.S. Walgreens and international Boots stores. It is comparable to Pague Menos as a national-scale physical drugstore chain with overlapping product categories of prescription, OTC, and personal care.

TypeOthers
Description

McKesson is a global pharmaceutical wholesale distributor and supply chain partner to retail pharmacies. It is comparable to Pague Menos as a participant in the drug distribution value chain, though McKesson operates upstream in wholesale rather than downstream retail.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pague Menos

Retail Pharmacypaguemenos.com.br

Pague Menos firmographics

Firmographics
Name
Pague Menos
Legal name
Pague Menos
Website
https://paguemenos.com.br
Company type
Private
Founded year
1981
Operating status
Operating
Headcount range
5,001–10,000 employees
Ownership category
akta.pro rank

Pague Menos industry classification

Industry
Product category
Retail Pharmacy
NAICS
Pharmacies and Drug Retailers (456110)
SIC
Retail-Drug Stores And Proprietary Stores (5912)
akta.pro primary industry
Retail & Community Pharmacies (Chain/Independent) (HLAFALAA)
akta.pro secondary industry
Value Pharmacies & Deep-Discount Pharmacy Retail (CRAEAHAB)

Keywords

  • Retail pharmacy services
  • Prescription medications
  • Over-the-counter drugs
  • Health and wellness products
  • Drugstore retail

Where Pague Menos is headquartered

Location

Headquarters

HQ city
Ceará
HQ country
Brazil
HQ region
Latin America

Markets served

Pague Menos business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Retail Pharmacy Sales: Pague Menos generates revenue through the retail sale of pharmaceutical products, health items, and related consumer goods across its pharmacy store network in Brazil.

Go-to-market motion1 record

Distribution channels1 record

Pague Menos product offering

Product offering

Core offering

Pague Menos operates a nationwide chain of retail pharmacies in Brazil, selling prescription medications, over-the-counter drugs, health and wellness products, and personal care items directly to individual consumers through physical storefronts. The chain's scale was significantly expanded through the 2021 acquisition of Extrafarma from Ultrapar for R$ 700 million, making it the second-largest drugstore operator in Brazil.

Product overview

Pague Menos is a Brazilian pharmacy chain retailer. The company operates as a retail pharmacy business offering pharmaceutical products and health-related goods to consumers. The company expanded its market presence through the acquisition of rival pharmacy chain Extrafarma from Ultrapar for R$ 700 million in 2021. No detailed product portfolio or service module information is available from the provided sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Retail pharmacy sales Retail sale of prescription medications, over-the-counter drugs, health and wellness products, and personal care items to Brazilian consumers through the Pague Menos physical pharmacy network.
  • Extrafarma pharmacy retail operations Wholly-owned retail pharmacy subsidiary offering pharmaceutical and health products under the Extrafarma brand, retained following Pague Menos's 2021 acquisition.

Companies that use Pague Menos

Customer profile

Segments1 record

Ideal customer profiles1 record

Pague Menos technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Pague Menos partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • UltraparcoreOthers · 18 March 2021Pague Menos completed the acquisition of rival pharmacy chain Extrafarma from Ultrapar for R$ 700 million. This strategic transaction significantly expanded Pague Menos' market presence, making it the second-largest player in the Brazilian drugstore sector.

Scale indicators3 records

Recent moves5 records

Expansion highlights2 records

Pague Menos competitors and assessment

Company assessment

Direct peers

  • Raia Drogasil: Raia Drogasil (RD) is the largest drugstore chain in Brazil, formed from the merger of Drogaria Raia and Drogasil. It is Pague Menos's primary direct competitor, operating a similar physical retail pharmacy model with overlapping product categories including prescription, OTC, personal care, and wellness across Brazil.
  • DPSP (Drogaria São Paulo & Drogarias Pacheco): DPSP is a major Brazilian pharmacy chain resulting from the combination of Drogaria São Paulo and Drogarias Pacheco, operating physical storefronts across multiple states. It directly competes with Pague Menos in the Brazilian drugstore retail sector with comparable product mix and customer base.
  • Panvel Farmácias: Panvel is a Brazilian pharmacy chain with a strong presence in the South region (Rio Grande do Sul and surrounding states), offering prescription drugs, OTC, beauty, and wellness products. It is comparable to Pague Menos as a multi-state physical retail pharmacy operator, though with a more regional footprint.

Regional players

  • Drogaria Araújo: Drogaria Araújo is one of the largest pharmacy chains in Minas Gerais, operating a physical retail pharmacy network with comparable product categories to Pague Menos. It is comparable as a Brazilian physical pharmacy chain but operates primarily within a single state rather than nationally.
  • Drogaria Venancio: Drogaria Venancio is a long-established pharmacy chain headquartered in Rio de Janeiro, operating physical storefronts with prescription, OTC, and health product offerings. It is comparable to Pague Menos as a Brazilian physical pharmacy retailer, though concentrated in the Rio de Janeiro metropolitan area.

Broad incumbents

  • CVS Health: CVS Health is the largest pharmacy retail chain in the United States, combining drugstores with pharmacy benefit management, insurance, and healthcare services. It is comparable to Pague Menos as a broad retail pharmacy operator at scale, though operating in a very different healthcare system.
  • Walgreens Boots Alliance: Walgreens Boots Alliance operates one of the largest global pharmacy retail footprints including U.S. Walgreens and international Boots stores. It is comparable to Pague Menos as a national-scale physical drugstore chain with overlapping product categories of prescription, OTC, and personal care.

Others

  • McKesson: McKesson is a global pharmaceutical wholesale distributor and supply chain partner to retail pharmacies. It is comparable to Pague Menos as a participant in the drug distribution value chain, though McKesson operates upstream in wholesale rather than downstream retail.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Pague Menos social profiles

Digital presence

Pague Menos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pague Menos leadership team

Management profile

Number of profiles

Profiles1 record

Pague Menos subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pague Menos funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pague Menos M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pague Menos

What does Pague Menos do?

Pague Menos operates a nationwide chain of retail pharmacies in Brazil, selling prescription medications, over-the-counter drugs, health and wellness products, and personal care items directly to individual consumers through physical storefronts. The chain's scale was significantly expanded through the 2021 acquisition of Extrafarma from Ultrapar for R$ 700 million, making it the second-largest drugstore operator in Brazil.

Is Pague Menos a public or private company?

Pague Menos is a private company. It is classified as public and is currently operating.

When was Pague Menos founded?

Pague Menos was founded in 1981. It employs 5,001 to 10,000 people.

Where is Pague Menos based?

Pague Menos is headquartered in Ceará, Brazil, in the Latin America region.

How does Pague Menos make money?

One revenue line is on record: retail Pharmacy Sales.

Who are Pague Menos's main competitors?

Direct peers on record are Raia Drogasil, DPSP (Drogaria São Paulo & Drogarias Pacheco) and Panvel Farmácias. Regional players are Drogaria Araújo and Drogaria Venancio. Broad incumbents are CVS Health and Walgreens Boots Alliance. McKesson is listed as an others.

Does Pague Menos have an API?

No public API is recorded for Pague Menos.

What industry is Pague Menos in?

Pague Menos's product category is Retail Pharmacy. Its primary akta.pro industry code is HLAFALAA, Retail & Community Pharmacies (Chain/Independent), with a secondary code of CRAEAHAB, Value Pharmacies & Deep-Discount Pharmacy Retail. Its NAICS code is 456110 and its SIC code is 5912.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pegnMercado Livre starts selling prescription medication within an hourMercado Livre launched its Envios Agora program to deliver prescription medications within an hour, starting in São Paulo. The move caused major pharmacy chains' shares to fall, with Pague Menos dropping 8%. The company plans to integrate 20 pharmacies in São Paulo this year.Brazil JournalDrogarias desabam: MELI vai vender antibióticos e GLP-1Mercado Livre began selling prescription drugs requiring receipt retention, including GLP-1 weight-loss pens and antibiotics, causing major pharmacy chains to fall. RD Saúde dropped 5.5%, Pague Menos 7.7%, and Panvel 6%. The company expects 20 pharmacies to sell on its platform by year-end, with first integrations in October.InfoMoneyRD, Pague Menos e Panvel: farmacêuticas desabam até 8% após anúncio do Mercado LivreMercado Livre announced it will sell prescription drugs, causing pharmaceutical stocks to fall on B3. RD Saúde dropped 5.38%, Pague Menos 8%, and Panvel 4.90%. The service launches Monday, with 20 pharmacies expected by year-end.ExameHypera, RD Saúde e Pague Menos: quem ganha (e quem perde) com canetas no SUS?Brazilian pharma stocks could be affected if the SUS includes weight-loss pens, with Hypera seen as a direct beneficiary. Private pharmacy chains like RD Saúde and Pague Menos may lose direct sales but could gain from increased foot traffic and dispensation contracts. Multinationals Novo Nordisk and Eli Lilly face increased competition from domestic manufacturers.ExameMateus, Assaí, Pague Menos: o aumento do Bolsa Família pode ser bom para essas açõesJP Morgan said the 15.04% Bolsa Família increase could boost retail sales in the North and Northeast, benefiting Grupo Mateus, Pague Menos, and Assaí. The minimum benefit rises to R$691, with payments starting October 19. The program now serves about 19.3 million families.InfoMoneyReajuste no Bolsa Família: quais varejistas da B3 podem ser beneficiadas?JPMorgan expects a 15% Bolsa Família raise in October to boost consumption, especially in the North and Northeast. The program's budget rises to R$179 billion in 2027, with benefits increasing from R$600 to R$691. Retailers like Grupo Mateus and Pague Menos could benefit, though higher interest rates may offset gains.ExameSplit Payment pode reduzir lucro de Magalu, Pague Menos e Centauro, diz SafraSafra estimates split payment under Brazil's tax reform could reduce profits of Magazine Luiza, Pague Menos, and Centauro by up to 2% in 2027. The mechanism reduces cash availability, increasing working capital needs and lowering financial income. The bank expects gradual adoption, with full implementation by 2028.InfoMoneyCom peso de canetas emagrecedoras, Itaú BBA revê estimativas para farmáciasItaú BBA revised its estimates for three pharmacy stocks after Q2 2026 results, keeping RD Saúde's price target at R$25, cutting Pague Menos to R$5.50, and raising Panvel to R$16. The bank raised Panvel's recommendation to buy, citing momentum and attractive valuation.InfoMoneyMounjaro pode fazer farmácias brasileiras viverem novo momento?Sales of patented synthetic medications in Brazil reached a record R$ 943 million in July, driven by strong volume growth despite lower realized prices. Morgan Stanley analysts attribute this resilience to the performance of GLP-1 drugs like Mounjaro and predict continued market growth for pharmacy retailers such as RD Saúde and Pague Menos. The broader retail pharmacy sector also showed healthy expansion with a 9.3% annual increase in sales.FolhaCada R$ 1 gasto com canetas emagrecedoras, clientes compram R$ 8 em outros produtos, diz CEO da Pague MenosPague Menos CEO Jonas Marques reported that GLP-1 weight loss pen sales generate significant cross-selling revenue, with customers spending R$ 8.14 on other products for every R$ 1 spent on the medication. The company faces high operational costs and security risks due to the expensive inventory required for these temperature-sensitive drugs. Additionally, the executive criticized recent regulatory moves by Anvisa that allow digital platforms like iFood and Mercado Livre to facilitate the sale of such medications.